COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN SPAIN

被引：3
|
作者：
Carrascosa, J. M. [1 ]
Vanaclocha, F. [2 ]
Caloto, T. [3 ]
Echave, M. [4 ]
Oyaguez, I [4 ]
Tencer, T. [5 ]
机构：
[1] Germans Trias & Pujol Univ Hosp, Dept Dermatol, Barcelona, Spain
[2] 12 Octubre Univ Hosp, Dept Dermatol, Madrid, Spain
[3] Celgene Corp, Dept Hlth Econ, Madrid, Spain
[4] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[5] Celgene Corp, Warren, NJ USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.555
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS31
引用
收藏
页码：A420 / A420
页数：1
相关论文
共 50 条
  • [21] COST OF MODERATE TO SEVERE PSORIASIS PATIENTS IN SPAIN
    Sanchez-Carazo, J. L.
    Dauden, E.
    Vanaclocha, F.
    Toribio, J.
    Pujol, R.
    Puig, L.
    Yebenes, M.
    Sabater, F. J.
    VALUE IN HEALTH, 2009, 12 (07) : A454 - A454
  • [22] Cost-utility analysis of eprosartan compared to enalapril and ramipril in the treatment of moderate to severe hypertension in Sweden
    Lindgren, P.
    Schwander, B.
    Zollner, Y.
    Jonsson, B.
    VALUE IN HEALTH, 2006, 9 (06) : A353 - A353
  • [23] COST-EFFECTIVENESS OF APREMILAST IN MODERATE-TO-SEVERE PSORIASIS IN CANADA
    Cawston, H.
    Damera, V
    Ektare, V
    Shear, N. H.
    Tencer, T.
    Liu, F. F.
    VALUE IN HEALTH, 2016, 19 (07) : A587 - A587
  • [24] Oral apremilast is active in the treatment of moderate to severe plaque psoriasis
    Papp, Kim
    Hu, Angela
    Day, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB147 - AB147
  • [25] Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence
    Sebastian Hinde
    Ros Wade
    Stephen Palmer
    Nerys Woolacott
    Eldon Spackman
    PharmacoEconomics, 2016, 34 : 587 - 596
  • [26] Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence
    Hinde, Sebastian
    Wade, Ros
    Palmer, Stephen
    Woolacott, Nerys
    Spackman, Eldon
    PHARMACOECONOMICS, 2016, 34 (06) : 587 - 596
  • [27] Review of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis
    Ivanic, Mirjana G.
    Thatiparthi, Akshitha
    Walia, Shikha
    Liao, Wilson
    Wu, Jashin J.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (08) : 837 - 843
  • [28] Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis
    Taheri, Saeed
    Fashami, Fatemeh Mirzayeh
    Peiravian, Farzad
    Yousefi, Nazila
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2019, 18 (02): : 1073 - 1085
  • [29] COST-UTILITY ANALYSIS OF MAINTENANCE TREATMENT WITH TACROLIMUS OINTMENT IN ADULTS AND CHILDREN WITH MODERATE AND SEVERE ATOPIC DERMATITIS
    Chambers, C.
    Bentley, A.
    VALUE IN HEALTH, 2010, 13 (03) : A147 - A147
  • [30] ANNUAL COST OF BIOLOGICAL THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN SPAIN
    Dominguez-Gil, A.
    Moreno, D.
    Garcia, D.
    Campo, C.
    VALUE IN HEALTH, 2011, 14 (07) : A505 - A505
12345